Cargando…

Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1

BACKGROUND: The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1–infected individuals are likely to progress to active...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesosky, Maia, Rangaka, Molebogeng X, Pienaar, Cara, Coussens, Anna K, Goliath, Rene, Mathee, Shaheed, Mwansa-Kambafwile, Judith, Maartens, Gary, Wilkinson, Robert J, Wilkinson, Katalin Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603269/
https://www.ncbi.nlm.nih.gov/pubmed/30256919
http://dx.doi.org/10.1093/cid/ciy823
_version_ 1783431485607378944
author Lesosky, Maia
Rangaka, Molebogeng X
Pienaar, Cara
Coussens, Anna K
Goliath, Rene
Mathee, Shaheed
Mwansa-Kambafwile, Judith
Maartens, Gary
Wilkinson, Robert J
Wilkinson, Katalin Andrea
author_facet Lesosky, Maia
Rangaka, Molebogeng X
Pienaar, Cara
Coussens, Anna K
Goliath, Rene
Mathee, Shaheed
Mwansa-Kambafwile, Judith
Maartens, Gary
Wilkinson, Robert J
Wilkinson, Katalin Andrea
author_sort Lesosky, Maia
collection PubMed
description BACKGROUND: The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1–infected individuals are likely to progress to active disease is unknown. METHODS: Thirteen analytes were measured from QuantiFERON Gold in-tube (QFT) plasma samples in 421 HIV-1–infected persons recruited within the screening and enrollment phases of a randomized, controlled trial of isoniazid preventive therapy. Blood for QFT was obtained pre-randomization. Individuals were classified into prevalent TB, incident TB, and control groups. Comparisons between groups, supervised learning methods, and weighted correlation network analyses were applied utilizing the unstimulated and background-corrected plasma analyte concentrations. RESULTS: Unstimulated samples showed higher analyte concentrations in the prevalent and incident TB groups compared to the control group. The largest differences were seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1α, transforming growth factor-α (TGF-α). A predictive model analysis using unstimulated analytes discriminated best between the control and prevalent TB groups (area under the curve [AUC] = 0.9), reasonably well between the incident and prevalent TB groups (AUC > 0.8), and poorly between the control and incident TB groups. Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups. Models using background-adjusted values performed poorly. CONCLUSIONS: Single plasma biomarkers are unlikely to distinguish between disease states in HIV-1 co-infected individuals, and combinations of biomarkers are required. The ability to detect prevalent TB is potentially important, as no blood test hitherto has been suggested as having the utility to detect prevalent TB amongst HIV-1 co-infected persons.
format Online
Article
Text
id pubmed-6603269
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-66032692019-07-05 Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1 Lesosky, Maia Rangaka, Molebogeng X Pienaar, Cara Coussens, Anna K Goliath, Rene Mathee, Shaheed Mwansa-Kambafwile, Judith Maartens, Gary Wilkinson, Robert J Wilkinson, Katalin Andrea Clin Infect Dis Articles and Commentaries BACKGROUND: The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1–infected individuals are likely to progress to active disease is unknown. METHODS: Thirteen analytes were measured from QuantiFERON Gold in-tube (QFT) plasma samples in 421 HIV-1–infected persons recruited within the screening and enrollment phases of a randomized, controlled trial of isoniazid preventive therapy. Blood for QFT was obtained pre-randomization. Individuals were classified into prevalent TB, incident TB, and control groups. Comparisons between groups, supervised learning methods, and weighted correlation network analyses were applied utilizing the unstimulated and background-corrected plasma analyte concentrations. RESULTS: Unstimulated samples showed higher analyte concentrations in the prevalent and incident TB groups compared to the control group. The largest differences were seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1α, transforming growth factor-α (TGF-α). A predictive model analysis using unstimulated analytes discriminated best between the control and prevalent TB groups (area under the curve [AUC] = 0.9), reasonably well between the incident and prevalent TB groups (AUC > 0.8), and poorly between the control and incident TB groups. Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups. Models using background-adjusted values performed poorly. CONCLUSIONS: Single plasma biomarkers are unlikely to distinguish between disease states in HIV-1 co-infected individuals, and combinations of biomarkers are required. The ability to detect prevalent TB is potentially important, as no blood test hitherto has been suggested as having the utility to detect prevalent TB amongst HIV-1 co-infected persons. Oxford University Press 2019-07-15 2018-09-26 /pmc/articles/PMC6603269/ /pubmed/30256919 http://dx.doi.org/10.1093/cid/ciy823 Text en © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles and Commentaries
Lesosky, Maia
Rangaka, Molebogeng X
Pienaar, Cara
Coussens, Anna K
Goliath, Rene
Mathee, Shaheed
Mwansa-Kambafwile, Judith
Maartens, Gary
Wilkinson, Robert J
Wilkinson, Katalin Andrea
Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1
title Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1
title_full Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1
title_fullStr Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1
title_full_unstemmed Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1
title_short Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1
title_sort plasma biomarkers to detect prevalent or predict progressive tuberculosis associated with human immunodeficiency virus–1
topic Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603269/
https://www.ncbi.nlm.nih.gov/pubmed/30256919
http://dx.doi.org/10.1093/cid/ciy823
work_keys_str_mv AT lesoskymaia plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT rangakamolebogengx plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT pienaarcara plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT coussensannak plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT goliathrene plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT matheeshaheed plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT mwansakambafwilejudith plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT maartensgary plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT wilkinsonrobertj plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1
AT wilkinsonkatalinandrea plasmabiomarkerstodetectprevalentorpredictprogressivetuberculosisassociatedwithhumanimmunodeficiencyvirus1